liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors
Christie NHS Fdn Trust, England.
Christie NHS Fdn Trust, England; Univ Manchester, England.
Ryhov Cty Hosp, Sweden.
Futurum Acad Hlth & Care, Sweden.
Show others and affiliations
2026 (English)In: Breast Cancer Research and Treatment, ISSN 0167-6806, E-ISSN 1573-7217, Vol. 216, no 1, article id 6Article in journal (Refereed) Published
Abstract [en]

Purpose Thymidine kinase 1 activity (TKa) has previously been demonstrated as a prognostic biomarker for progression-free survival (PFS) in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC), but its optimal use remains undefined. This study evaluated the prognostic performance of TKa across multiple sampling time points and thresholds in patients receiving first-line CDK4/6 inhibitor plus aromatase inhibitor therapy. Methods TKa was measured (DiviTum (R) assay) at baseline (BL), cycle 1 day 15 (C1D15), and cycle 2 day 1 (C2D1) in patients enrolled in the PDM-MBC study (n = 90). Thresholds for PFS discrimination were identified using maximally selected rank statistics, with predefined cut-offs tested for comparison. Prognostic performance was assessed using the corrected Akaike information criterion (AICc) and Harrell's concordance index (C-index). Results TKa was prognostic at all time points. Data-derived thresholds identified groups with differing PFS and overall survival (OS), and predefined cut-offs (>= 50, >= 100, >= 250 DiviTum (R) units of Activity [DuA]) also discriminated survival outcomes. BL and C2D1 models performed better than C1D15 and comparably to multi-time-point models. Among patients with BL TKa >= 250 DuA, suppression to < 100 DuA at C1D15 was associated with longer median PFS (23.9 vs. 10.3 months; p = 0.034). Conclusion Baseline TKa provides prognostic information, with potential added value from repeated testing in those with high baseline levels. TKa behaves as a continuous biomarker of risk, and continuous modelling may offer more clinically informative individual risk estimation, while thresholds may retain value for specific clinical contexts. Validation in larger cohorts is warranted to support integration into routine practice.

Place, publisher, year, edition, pages
SPRINGER , 2026. Vol. 216, no 1, article id 6
Keywords [en]
Advanced breast cancer; CDK4/6 inhibitors; Aromatase inhibitors; Prognostic biomarker; Thymidine kinase 1; Survival analysis
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-221777DOI: 10.1007/s10549-025-07879-0ISI: 001688231400001PubMedID: 41670750Scopus ID: 2-s2.0-105029715880OAI: oai:DiVA.org:liu-221777DiVA, id: diva2:2044861
Note

Funding Agencies|Foundation for Clinical Cancer Research in Jnkping [180424-2, 20201116-1]; Swedish Breast Cancer Association [F2018-03, F2019-005]; Linkping University; The Christie Charity [charity number 1201654]; Svenska Lkaresllskapet [SLS-874931]; Futurum - Akademin fr Hlsa och Vrd, Region Jnkpings lns [FUTURUM- 989624]; Forskningsrdet i Sydstra Sverige [FORSS-989664, FORSS-995301]; Percy Falk Foundation [2018, 2019]; Cancerfonden [23 2760 Fk]; ALF grants from Region stergtland [R-1013092]

Available from: 2026-03-10 Created: 2026-03-10 Last updated: 2026-04-24

Open Access in DiVA

fulltext(2073 kB)32 downloads
File information
File name FULLTEXT01.pdfFile size 2073 kBChecksum SHA-512
a8c36d1c4982e617fa6184cd3c206715a70768947052d56f53ec3e09d8cdc8cab14407ad9405a0c84f8ab7c6544d356c7beb9725de505b3d0c0cc8177530a6b2
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Albu-Kareem, AhmedEkholm, Maria
By organisation
Department of OncologyDivision of Surgery, Orthopedics and OncologyFaculty of Medicine and Health Sciences
In the same journal
Breast Cancer Research and Treatment
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 32 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 34 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf